Quantcast
Last updated on April 24, 2014 at 5:30 EDT

Latest C1 Stories

2014-01-29 08:31:10

Expansion Includes New State-of-the Art Fermentation Lab, Significantly Increased Floor Space and Additional Scientific Staff JUPITER, Fla., Jan. 29, 2014 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that the expansion of its research...

2013-05-29 12:21:40

President and CEO, Mark Emalfarb, to Provide Update on Dyadic's C1 Enzyme Technology and Progress Towards Producing Cellulosic Sugars for Fuels and Chemicals JUPITER, Fla., May 29, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), announced today that its President and CEO, Mark Emalfarb, will present at the World Biotechnology Congress 2013 in Boston, Massachusetts and the BIO World Congress on Industrial Biotech in Montreal, Canada. (Logo:...

2012-05-01 02:23:48

JUPITER, Fla., May 1, 2012 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic")(OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, biochemical, biopharmaceutical and industrial enzyme industries, announced today that Abengoa Bioenergy New Technologies, Inc. ("Abengoa") has agreed to pay Dyadic $5.5 million for an expansion of its rights under the non-exclusive license agreement the...

2012-02-29 08:15:00

JUPITER, Fla., Feb. 29, 2012 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that it has entered into a research, development and license agreement with a leading global provider of nutritional ingredient solutions to use Dyadic's patented and proprietary C1...

2011-03-29 09:54:00

EXTON, Pa., March 29, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 clinical study to evaluate the safety and efficacy of C1 Esterase Inhibitor [Human] for the treatment of acute antibody-mediated rejection (AMR) in recipients of donor-specific cross-match positive kidney transplants. This randomized, double blind, placebo-controlled study will evaluate the safety, tolerability and clinical effect of C1 Esterase Inhibitor [Human] for...

2011-02-22 08:15:00

JUPITER, Fla., Feb. 22, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has launched FibreZyme® G200, a next generation, high performance enzyme designed to improve paper quality and improve the economics of various pulp and paper...

2010-08-05 07:00:00

EXTON, Pa., Aug. 5 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that data from Phase 3 studies of Cinryze(TM) (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary...

2010-06-21 08:15:00

JUPITER, Fla., June 21 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI), a global biotechnology company whose cutting-edge C1 platform technology addresses the needs of the multi-billion dollar biofuels market by producing enzymes at industrial scale which efficiently convert biomass into ethanol and other forms of alternative energy, announced today that it has engaged the influential consulting firm, The Abraham Group, to provide strategic advice and transactional...

2010-03-25 08:15:00

JUPITER, Fla., March 25 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI), a leading-edge early-stage biotechnology company ("Dyadic"), today announced financial results for the year ended December 31, 2009. The financial information contained in this press release should be read in conjunction with the financial statements, footnotes and independent auditors' report which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic's website at...

2009-12-14 08:30:00

JUPITER, Fla., Dec. 14 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced today that it has extended its collaboration with The Scripps Research Institute ("Scripps") by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ("C1"). This agreement is a continuation of the successful relationship between the two organizations which began in March 2006 when Dyadic engaged Scripps to annotate...